bioAffinity Technologies Free Cash Flow (FCF) History (BIAF)

bioAffinity Technologies reported −$9.4M in free cash flow for fiscal 2025, a decrease of $2.0M from the previous fiscal year, with a free cash flow margin of −152.38%.

View full bioAffinity Technologies company overview

bioAffinity Technologies free cash flow by year

bioAffinity Technologies annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31−$9.4M−$2.0M−152.38%
20242024-12-31−$7.3M−$1.3M−78.44%
20232023-12-31−$6.1M−$1.8M−239.32%
20222022-12-31−$4.3M−89336.50%

bioAffinity Technologies free cash flow growth trends

bioAffinity Technologies's latest reported quarter, Q2 2026, generated −$3.3M in free cash flow, a decrease of $630,441 year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review bioAffinity Technologies filings at SEC.gov ↗